Revenue
2019
2020
2021
2022
2023
2024
2025
Nurix Therapeutics, Inc. (NRIX)
Price$26.14Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M | $17.8M | $31.1M |
| Research & development | $316.9M | $221.6M | $189.1M | $184.5M | $116.4M | $66.5M | $45.0M |
| Operating expenses | $369.6M | $267.6M | $232.1M | $222.5M | $147.6M | $82.8M | $53.4M |
| Operating income | −$285.7M | −$213.0M | −$155.1M | −$183.9M | −$117.9M | −$65.0M | −$22.2M |
| Operating margin | −340.16% | −390.52% | −201.41% | −476.01% | −396.26% | −364.66% | −71.46% |
| EBITDA | −$276.9M | −$203.7M | −$147.5M | −$178.5M | −$115.1M | −$62.8M | −$19.9M |
| EBITDA margin | −329.75% | −373.44% | −191.63% | −462.16% | −386.88% | −352.43% | −63.90% |
| Net income | −$264.5M | −$193.6M | −$143.9M | −$180.4M | −$117.2M | −$43.2M | −$21.7M |
| Net profit margin | −314.90% | −354.85% | −186.98% | −466.93% | −393.93% | −242.66% | −69.74% |
| Basic EPSper basic share | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | -$2.76 | -$6.59 |
| Diluted EPSper diluted share | -$3.05 | -$2.88 | -$2.65 | -$3.71 | -$2.73 | -$2.76 | -$6.59 |
Owners
Reported shareholders
8.45%of listed shares
BlackRock, Inc.8.77M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.45%8.77M shares |
Vestal Point Capital, LP | 7.76%8.05M shares |
Deep Track Capital, LP | 7.45%7.74M shares |
Rubric Capital Management LP | 6.96%7.23M shares |
FMR LLC | 5.29%5.49M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 5.24%5.44M shares |
MORGAN STANLEY | 4.59%4.76M shares |
STATE STREET CORP | 4.51%4.68M shares |
BAKER BROS. ADVISORS LP | 4.49%4.66M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.33%4.5M shares |
PERCEPTIVE ADVISORS LLC | 4.16%4.32M shares |
Redmile Group, LLC | 3.93%4.07M shares |
GENERAL ATLANTIC, L.P. | 2.92%3.03M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.44%2.54M shares |
Pictet Asset Management Holding SA | 2.27%2.35M shares |
ARK Investment Management LLC | 1.73%1.79M shares |
Capital World Investors | 1.72%1.79M shares |
Trails Edge Capital Partners, LP | 1.52%1.57M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.43%1.48M shares |
CITADEL ADVISORS LLC | 1.42%1.48M shares |
Percentages use 103.78M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 · 10b5-1 | Ring ChristineChief Legal Officer | SellCommon Stock | 28.9K | $20.06 | $580.4K | 13.6K |
| Jun 25, 2026Form 4 · 10b5-1 | Hansen GwennChief Scientific Officer | SellCommon Stock | 5.4K | $20.00 | $107.9K | 115.0K |
| Jun 2, 2026Form 4 · 10b5-1 | Ring ChristineChief Legal Officer | SellCommon Stock | 8.1K | $16.60 | $135.3K | 13.6K |
| May 5, 2026Form 4 · 10b5-1 | van Houte HansChief Financial Officer | SellCommon Stock | 582 | $17.18 | $10.0K | 37.6K |
| May 5, 2026Form 4 · 10b5-1 | van Houte HansChief Financial Officer | SellCommon Stock | 13.5K | $16.58 | $223.4K | 38.2K |